Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma
{{output}}
Objective: Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survi... ...
